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SHORT COMMUNICATION
Whole exome sequencing identifies a mutation in thrombomodulin as the
genetic cause of a suspected platelet disorder in a family with normal
platelet function
Annabel Maclachlan1, Gerry Dolan2, Charlotte Grimley2, Steve P. Watson1, Neil V. Morgan1,
& on behalf of the UK GAPP Study Group
1Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK and 2Nottingham
Haemophilia Centre, Nottingham University Hospital, Nottingham, UK
Abstract
Here, we describe a mother and son with a lifelong bleeding tendency and posttraumatic bleeding
who were recruited to the UK Genotyping and Phenotyping of Platelets (GAPP) study with a
suspected platelet function disorder. However, despite a clinically significant bleeding score, both
had normal platelet counts and normal platelet function. The patients’ blood was analyzed by light
transmission aggregometry and genotyping by whole exome sequencing, as outlined by the GAPP
study. Approximately 25 000 genetic variants were found for each patient as a result of sequencing
and were filtered using a specialized bioinformatics pipeline. A heterozygous variant displaying
autosomal dominant inheritance (c.1611 C>A) was found in the gene THBD which encodes the
glycoprotein thrombomodulin. This sequence change results in a stop codon (p.Cys537Stop) and
truncation of the protein and has been previously described in two other families with bleeding
events which suggests it may be a recurrent mutation. In summary, this study shows that patients
with a suspected platelet disorder but who present with a normal pattern of platelet aggregation
should be investigated for defects in nonplatelet genes.
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Introduction
Inherited platelet disorders (IPDs) are a heterogeneous group of
disorders associated with normal or reduced platelet counts and
bleeding diatheses of varying severities [1,2]. The identification
of the underlying cause of IPDs is clinically challenging, and, as a
consequence, a DNA-based approach has a highly important role
in the investigation of these patients [3]. The UK Genotyping and
Phenotyping of Platelets (GAPP) study recruits patients with mild
bleeding who have been clinically diagnosed with a suspected
platelet function disorder. However, approximately 60% of
patients recruited have no apparent platelet defect, despite having
a clinically significant bleeding score. A mother and son were
recruited to the GAPP study with a lifelong bleeding tendency,
including posttraumatic bleeding, but presented with normal pla-
telet and platelet-rich plasma (PRP) counts (4.2 × 108/mL and 3 ×
108/mL, respectively), normal clotting factors, and normal platelet
function. Factor IX genetics were also normal; however, pro-
thrombin consumption index was abnormal. To study these
patients further, we have used a forward genetic approach by
implementing whole exome sequencing (WES) focusing on non-
platelet genes.
Methods
The mother and son were evaluated, and a clinical history was taken
including bleeding scores using the International Society of
Haemostasis and Thrombosis bleeding assessment tool [4]. Blood
was obtained from both patients, PRP was isolated, and platelet
function was tested using lumiaggregometry. A dual Chrono-log
460VS lumiaggregometer (Chrono-log, LabMedics, UK) was used
to test patient PRP using a range of concentrations of agonists: ADP
(100 µM, 30 µM and 10 µM, 3 µM, 1 µM), adrenaline (30 µM and
10 µM), arachidonic acid (2.25 mM and 1.5 mM), U46619 (3 µM
and 1 µM), PAR1 agonist (100 µM, 30 µM, and 10 µM), PAR4
agonist (500 µM, 250 µM, and 100 µM), collagen (3 µg/mL, 1 µg/
mL, and 0.3 µg/mL), collagen-related peptide (CRP) (1 µg/mL), and
ristocetin (1.25 mg/mL and 1.5 mg/mL). Platelet ATP secretion from
dense granules was also measured using the luciferase assay and
agonists: ADP (100 µM), adrenaline (30 µM), U46619 (3 µM),
PAR1 agonist (100 µM), PAR4 agonist (500 µM), collagen (3 µg/
mL), and CRP (1 µg/mL) [5].
WES was performed with a minimum of 1μg DNA extracted
from peripheral blood. Enrichment of the coding regions and
intron/exon boundaries was completed with the SureSelect
Human All Exon 50 Mb kit (Agilent Technologies, UK) accord-
ing to the manufacturer’s instructions and analyzed as previously
described [6]. The novelty of filtered variants was elucidated by
comparison to known variants present within dbSNP139, exome
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aggregation consortium (ExAC), the 1000 Genomes Project and
EVS (evs.gs.washington.edu/EVS/), as well as the data generated
from over 1200 exomes of in-house controls sequenced and
analyzed using the same protocol [7]. Copy number variants
were detected using ExomeDepth [8]. Variants were then called
using a custom-made bioinformatics pipeline to determine candi-
date variants from the WES data as previously shown by the
GAPP study [6]. Sanger sequencing was then performed on
candidate variants to confirm the variants, thereby ruling out the
possibility of false-positive results of WES.
Results
The family pedigree in this study displays an autosomal dominant
inheritance for the bleeding phenotype (Figure 1). An extensive
bleeding history throughout the pedigree was evident. The index
case, a male III:2, suffered from hemarthroses, soft tissue, and
muscle bleeding in childhood and a spontaneous rectal sheath
hematoma in 2006. His mother, II:4, was admitted to hospital
for 3 weeks after wisdom teeth extraction and suffered bleeding
after tonsillectomy and menorrhagia requiring hysterectomy
(complicated by bleeding). His grandmother, I:1, suffered from
bleeding after dental extraction requiring transfusion, easy bruis-
ing, and postpartum hemorrhage. His maternal aunt, II:3, had
extensive bleeding which resorted in a nephrectomy following a
road-traffic accident and maternal uncle II:2 lost an eye as a result
of traumatic bleeding as a child as well as suffering from bleeding
post dental extraction and soft tissue and muscle bleeding.
Patients’ III:2 and II:4 platelet aggregation traces showed
normal responses to all the concentrations of agonists that were
tested. Normal platelet granule secretion values were also
observed in both patients in response to all agonists (data not
shown). Therefore, no defect in platelet aggregation or secretion
was detected in either of the patients tested.
WES identified 26 125 variants in II:4 and 25 969 variants in
III:2. The bioinformatics pipeline was used to narrow down the
variants with a series of filtering steps. Following the alignment
step and determining the novelty of the variants, they were fil-
tered against a custom-made panel of 856 genes known or pre-
dicted to be associated with platelet count or function,
coagulation, or endothelial cell function. The remaining variants
were then filtered by frequency; variants with a minor allele
frequency (MAF) of more than or equal to 0.01 were excluded
as were any synonymous changes. Comparison of both patients
with a MAF ≤ 0.01 reduced to a total of 17 sequence variants.
Pathogenicity prediction tools (Mutation Taster, Phastcons, SIFT,
Provean etc.) were then utilized and the variants were classified as
outlined by the American College of Medical Genetics and
Genomics (ACMG) [9]. Candidate sequence variants were
selected and reduced on the basis of a pathogenic prediction in
at least three out of four of the prediction tools. This left candi-
date variants in five genes: APC, PDE3A, ACE, OCLN, and
THBD (Table I). All previously mentioned variants were classi-
fied as being of “uncertain significance” by the ACMG except for
THBD which was classified as “pathogenic.” Sanger sequencing
confirmed that the genetic variant in THBD (c.1611C>A) was
present in both patients.
Discussion
Extensive lumiaggregometry performed in both patients estab-
lished that there was no clear platelet function defect. The
THBD sequence variant identified in this family which encodes
the protein thrombomodulin (c.1611C>A, p.Cys537Stop) had
been previously reported to cause a similar bleeding diathesis
[10,11]. Thrombomodulin, a glycoprotein, is expressed on the
surface of endothelial cells and normally serves as a cofactor for
thrombin [12]. In a normal state, thrombomodulin forms a com-
plex with thrombin reducing blood coagulation by activation of
protein C, therefore inactivating factors Va and VIIIa, cofactors
highly involved in the coagulation cascade, and promoting fibri-
nolysis. However, the genetic variant in these patients leads to a
stop codon, resulting in premature termination of transcription
and hence a truncated form of the protein. Due to the truncation,
the protein is shed from the endothelial cell membrane into the
blood plasma. The increase of soluble thrombomodulin promotes
protein C activation and is also seen in several pathologic condi-
tions associated with endothelial dysfunction [13,14]. This there-
fore reduces thrombin generation within a potential thrombus,
resulting in the phenotype of posttraumatic bleeding [10].
Furthermore, this concurs with the abnormal prothrombin con-
sumption index observed in the patients tested. This is a rare
example of where a gain-of-function mutation in an anticoagulant
factor causes a bleeding disorder [11].
Conclusions
The genetic cause of bleeding in both patients I:2 and II:1
recruited to the GAPP study has been elucidated as a genetic
variant in the gene THBD using next-generation sequencing. The
same genetic variant in THBD has previously been shown to
cause a bleeding phenotype within affected individuals [10,11].
This can, therefore, explain the cause of bleeding in II:4 and III:2
and suggests that it may be a recurrent mutation.
Figure 1. Identification of a THBD mutation in a
family with a dominant form of inherited
bleeding with normal platelet aggregation and
secretion. Pedigree shows affected individuals
as shaded symbols and asterisks (*) indicate
patients (II:4 and III:2) whose whole exomes
were sequenced.
2 A. Maclachlan et al. Platelets, Early Online: 1–3
Funding
The work in the author’s laboratories is supported by the British Heart
Foundation (PG/13/36/30275; FS/15/18/31317).
Declaration of interest
The authors report no conflict of interest.
References
1. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen
S, Liesner RJ, Minford A, Mumford AD, Parapia LA, Perry DJ,
et al. A review of inherited platelet disorders with guidelines for
their management on behalf of the UKHCDO. Br J Haematol
2006;135(5):603–633.
2. Nurden A, Nurden P. Advances in our understanding of the mole-
cular basis of disorders of platelet function. J Thromb Haemost
2011;9(Suppl 1):76–91.
3. Leo VC, Morgan NV, Bem D, Jones ML, Lowe GC, Lordkipanidze
M, Drake S, Simpson MA, Gissen P, Mumford A, et al. Use of next-
generation sequencing and candidate gene analysis to identify
underlying defects in patients with inherited platelet function dis-
orders. J Thromb Haemost 2015;13(4):643–650.
4. Lowe GC, Lordkipanidze M, Watson SP. Utility of the ISTH bleed-
ing assessment tool in predicting platelet defects in participants with
suspected inherited platelet function disorders. J Thromb Haemost
2013;11(9):1663–1668. doi: 10.111/jth.12332.
5. Dawood BB, Lowe GC, Lordkipanidze M, Bem D, Daly ME,
Makris M, Mumford A, Wilde JT, Watson SP. Evaluation of
participants with suspected heritable platelet function disorders
including recommendation and validation of a streamlined agonist
panel. Blood 2012;120(25):5041–5049.
6. Johnson B, Lowe GC, Futterer J, Lordkipanidze M, MacDonald D,
Simpson MA, Sanchez Guiu I, Drake S, Bem D, Leo V, et al. Whole
exome sequencing identifies genetic variants in inherited thrombo-
cytopenia with secondary qualitative function defects.
Haematologica 2016;101(10):1170–1179.
7. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell
T, O’Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB, et al.
Analysis of protein-coding genetic variation in 60,706 humans.
Nature 2016;536(7616):285–291. doi: 10.1038/nature19057.
8. Plagnol V, Curtis J, Epstein M, Mok KY, Stebbings E, Grigoriadou
S, Wood NW, Hambleton S, Burns SO, Thrasher AJ, et al. A robust
model for read count data in exome sequencing experiments and
implications for copy number variant calling. Bioinformatics
(Oxford, England) 2012;28(21):2747–2754.
9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody
WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines
for the interpretation of sequence variants: a joint consensus recom-
mendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet
Med 2015;17(5):405–424.
10. Langdown J, Luddington RJ, Huntington JA, Baglin TP. A her-
editary bleeding disorder resulting from a premature stop codon
in thrombomodulin (p.Cys537Stop). Blood 2014;124(12):1951–
1956.
11. Dargaud Y, Scoazec JY, Wielders SJH, Trzeciak C, Hackeng TM,
Négrier C, Hemker HC, Lindhout T, Castoldi E. Characterization of
an autosomal dominant bleeding disorder caused by a thrombomo-
dulin mutation. Blood 2015;125(9):1497–1501.
12. Weiler H, Isermann BH. Thrombomodulin. J Thromb Haemost
2003;1(7):1515–1524.
13. Dahlback B, Villoutreix BO. The anticoagulant protein C path-
way. FEBS Lett 2005;579(15):3310–3316. Epub 2005 Mar 13.
14. Kurosawa S, Stearns-Kurosawa DJ, Kinasewitz GT. Soluble
thrombomodulin: a sign of bad times. Crit Care Med 2008;36
(3):985–987. doi: 10.1097/CCM.0B013E318165FDA7.
Table I. Filtering pipeline showing the filtering strategy takenwhile selecting genetic variants as candidates in two affected family members (II:4 and III:2) with
normal platelet function following extensive laboratory testing.
II:4 III:2
Total number of variants identified by WES 26 125 25 969
Total number of variants (excluding synonymous) with a MAF ≤0.01 2320 2376
Shared significant variants from the panel of platelet and endothelial cell genes with a MAF ≤0.01 17
Total number of novel variants 181 152
Total number of shared novel variants 50
Total number of shared panel genes predicted to be pathogenic using all bioinformatics tools 5 (APC, PDE3A, ACE, OCLN, and THBD)
DOI: 10.1080/09537104.2017.1283011 Whole exome sequencing identifies a mutation in thrombomodulin 3
